Cargando…

Integrated genomics of ovarian xenograft tumor progression and chemotherapy response

BACKGROUND: Ovarian cancer is the most deadly gynecological cancer with a very poor prognosis. Xenograft mouse models have proven to be one very useful tool in testing candidate therapeutic agents and gene function in vivo. In this study we identify genes and gene networks important for the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stuckey, Ashley, Fischer, Andrew, Miller, Daniel H, Hillenmeyer, Sara, Kim, Kyu K, Ritz, Anna, Singh, Rakesh K, Raphael, Benjamin J, Brard, Laurent, Brodsky, Alexander S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155912/ https://www.ncbi.nlm.nih.gov/pubmed/21781307 http://dx.doi.org/10.1186/1471-2407-11-308

Ejemplares similares

Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells
por: Kim, Kyu Kwang, et al.
Publicado: (2010)

Expression Profiling of Primary and Metastatic Ovarian Tumors Reveals Differences Indicative of Aggressive Disease
por: Brodsky, Alexander S., et al.
Publicado: (2014)

Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C
por: Kim, Kyu Kwang, et al.
Publicado: (2012)

Efficacy of a Non-Hypercalcemic Vitamin-D2 Derived Anti-Cancer Agent (MT19c) and Inhibition of Fatty Acid Synthesis in an Ovarian Cancer Xenograft Model
por: Moore, Richard G., et al.
Publicado: (2012)

Identification of Ovarian Cancer Metastatic miRNAs
por: Vang, Souriya, et al.
Publicado: (2013)

Correction: Identification of Ovarian Cancer Metastatic miRNAs
por: Vang, Souriya, et al.
Publicado: (2014)

Iron(III)-Salophene: An Organometallic Compound with Selective Cytotoxic and Anti-Proliferative Properties in Platinum-Resistant Ovarian Cancer Cells
por: Lange, Thilo S., et al.
Publicado: (2008)

Correction: Iron(III)-Salophene: An Organometallic Compound with Selective Cytotoxic and Anti-Proliferative Properties in Platinum-Resistant Ovarian Cancer Cells
por: Lange, Thilo S., et al.
Publicado: (2008)

Apoptotic and chemotherapeutic properties of iron (III)-salophene in an ovarian cancer animal model
por: Lange, Thilo S, et al.
Publicado: (2009)

Bithionol inhibits ovarian cancer cell growth In Vitro - studies on mechanism(s) of action
por: Ayyagari, Vijayalakshmi N, et al.
Publicado: (2014)

Assessment of acyl-CoA cholesterol acyltransferase (ACAT-1) role in ovarian cancer progression—An in vitro study
por: Ayyagari, Vijayalakshmi N., et al.
Publicado: (2020)

Induction of cytotoxicity, apoptosis and cell cycle arrest by 1-t-butyl carbamoyl, 7-methyl-indole-3-ethyl isothiocyanate (NB7M) in nervous system cancer cells
por: Brard, Laurent, et al.
Publicado: (2009)

Organometallic Iron(III)-Salophene Exerts Cytotoxic Properties in Neuroblastoma Cells via MAPK Activation and ROS Generation
por: Kim, Kyu Kwang, et al.
Publicado: (2011)

Targeting HER2 in patient‐derived xenograft ovarian cancer models sensitizes tumors to chemotherapy
por: Harris, Faye R., et al.
Publicado: (2018)

Chemotherapy-radiation interactions in human cervix carcinoma xenografts.
por: Tonkin, K. S., et al.
Publicado: (1988)

Variation in response of xenografts of colo-rectal carcinoma to chemotherapy.
por: Nowak, K., et al.
Publicado: (1978)

Chemotherapy of human breast-carcinoma xenografts.
por: Bailey, M. J., et al.
Publicado: (1980)

Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines
por: Ayyagari, Vijayalakshmi N., et al.
Publicado: (2017)

Evaluation of the cytotoxicity of the Bithionol-paclitaxel combination in a panel of human ovarian cancer cell lines
por: Ayyagari, Vijayalakshmi N., et al.
Publicado: (2017)

Ovarian tumour xenografts in the study of the biology of human epithelial ovarian cancer.
por: Friedlander, M. L., et al.
Publicado: (1985)

Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models
por: Oliva, P, et al.
Publicado: (2012)

Isothiocyanate NB7M causes selective cytotoxicity, pro-apoptotic signalling and cell-cycle regression in ovarian cancer cells
por: Singh, R K, et al.
Publicado: (2008)

The response to chemotherapy of a variety of human tumour xenografts.
por: Steel, G. G., et al.
Publicado: (1983)

A Novel Walking Activity Recognition Model for Rotation Time Series Collected by a Wearable Sensor in a Free-Living Environment
por: Brard, Raphaël, et al.
Publicado: (2022)

Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model
por: Lindenblatt, Dennis, et al.
Publicado: (2014)

Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models
por: Koussounadis, Antonis, et al.
Publicado: (2016)

Equine ovarian tissue xenografting: impacts of cooling, vitrification, and VEGF
por: Souza, Samara Silva, et al.
Publicado: (2021)

Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model
por: Ishikura, Nobuyuki, et al.
Publicado: (2019)

Propranolol blocks osteosarcoma cell cycle progression, inhibits angiogenesis and slows xenograft growth in combination with cisplatin-based chemotherapy
por: Solernó, Luisina M., et al.
Publicado: (2022)

A Novel Antibody-Drug Conjugate Targeting Nectin-2 Suppresses Ovarian Cancer Progression in Mouse Xenograft Models
por: Sim, Yun Hee, et al.
Publicado: (2022)

First In-Mouse Development and Application of a Surgically Relevant Xenograft Model of Ovarian Carcinoma
por: Helland, Øystein, et al.
Publicado: (2014)

ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models
por: Yeom, Dong-Hoon, et al.
Publicado: (2020)

Experimental combination and single-agent chemotherapy in human lung-tumour xenografts.
por: Shorthouse, A. J., et al.
Publicado: (1982)

Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer
por: Dobbin, Zachary C., et al.
Publicado: (2014)

Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies
por: Heo, Eun Jin, et al.
Publicado: (2017)

Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts
por: Ricci, Francesca, et al.
Publicado: (2019)

Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts
por: Srivastava, Pragya, et al.
Publicado: (2015)

Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis
por: Shankar, Sharmila, et al.
Publicado: (2008)

Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer
por: Shen, Yen Ting, et al.
Publicado: (2019)

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
por: Riggs, McKayla J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_imkdp1g7f4n87bhhd43odbphps